BR112021025124A2 - Composto, composição farmacêutica, kit para a preparação da composição farmacêutica, métodos de imagiologia e radioterapia do corpo de mamífero, de detecção, diagnóstico, prognóstico, previsão do resultado, cirurgia, estadiamento, tratamento, terapia, radioterapia, monitoramento do tratamento, monitoramento da progressão da doença e/ou monitoramento da terapia e de obtenção de uma imagiologia de locais e/ou tratamento de condições associadas à superexpressão ou localização de cmet in vivo, e, uso - Google Patents
Composto, composição farmacêutica, kit para a preparação da composição farmacêutica, métodos de imagiologia e radioterapia do corpo de mamífero, de detecção, diagnóstico, prognóstico, previsão do resultado, cirurgia, estadiamento, tratamento, terapia, radioterapia, monitoramento do tratamento, monitoramento da progressão da doença e/ou monitoramento da terapia e de obtenção de uma imagiologia de locais e/ou tratamento de condições associadas à superexpressão ou localização de cmet in vivo, e, usoInfo
- Publication number
- BR112021025124A2 BR112021025124A2 BR112021025124A BR112021025124A BR112021025124A2 BR 112021025124 A2 BR112021025124 A2 BR 112021025124A2 BR 112021025124 A BR112021025124 A BR 112021025124A BR 112021025124 A BR112021025124 A BR 112021025124A BR 112021025124 A2 BR112021025124 A2 BR 112021025124A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- pharmaceutical composition
- monitoring
- radiotherapy
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
Abstract
composto, composição farmacêutica, kit para a preparação da composição farmacêutica, métodos de imagiologia e radioterapia do corpo de mamífero, de detecção, diagnóstico, prognóstico, previsão do resultado, cirurgia, estadiamento, tratamento, terapia, radioterapia, monitoramento do tratamento, monitoramento da progressão da doença e/ou monitoramento da terapia e de obtenção de uma imagiologia de locais e/ou tratamento de condições associadas à superexpressão ou localização de cmet in vivo, e, uso. são descritos compostos, em particular, compostos compreendendo um peptídeo cíclico de ligação a cmet para administração humana ou animal e métodos de uso dos mesmos. em particular, são descritos compostos adequados para a preparação de um agente para uso em imagiologia e/ou radioterapia. também são descritos uma composição farmacêutica e um kit para a preparação da composição farmacêutica. também são descritos métodos de imagiologia usando o composto ou a composição farmacêutica, tais como detecção, diagnóstico, prognóstico, previsão do resultado, cirurgia, estadiamento, tratamento, terapia, radioterapia, monitoramento do tratamento, monitoramento da progressão da doença e/ou monitoramento da terapia de doenças como o câncer. adicionalmente descrito é o uso do composto ou da composição farmacêutica como pelo menos um dentre, ou ambos, um agente de imagiologia e um agente radioterapêutico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1908573.7A GB201908573D0 (en) | 2019-06-14 | 2019-06-14 | Compounds and methods of use |
| GBGB2004360.0A GB202004360D0 (en) | 2020-03-26 | 2020-03-26 | Compounds and methods of use |
| PCT/GB2020/051442 WO2020249980A1 (en) | 2019-06-14 | 2020-06-15 | Compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021025124A2 true BR112021025124A2 (pt) | 2022-01-25 |
Family
ID=71120198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025124A BR112021025124A2 (pt) | 2019-06-14 | 2020-06-15 | Composto, composição farmacêutica, kit para a preparação da composição farmacêutica, métodos de imagiologia e radioterapia do corpo de mamífero, de detecção, diagnóstico, prognóstico, previsão do resultado, cirurgia, estadiamento, tratamento, terapia, radioterapia, monitoramento do tratamento, monitoramento da progressão da doença e/ou monitoramento da terapia e de obtenção de uma imagiologia de locais e/ou tratamento de condições associadas à superexpressão ou localização de cmet in vivo, e, uso |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220273830A1 (pt) |
| EP (1) | EP3983019A1 (pt) |
| JP (1) | JP2022537946A (pt) |
| KR (1) | KR20220034777A (pt) |
| CN (1) | CN114222592A (pt) |
| AU (1) | AU2020291197A1 (pt) |
| BR (1) | BR112021025124A2 (pt) |
| CA (1) | CA3142866A1 (pt) |
| GB (2) | GB2598676A (pt) |
| MX (1) | MX2021015467A (pt) |
| SG (1) | SG11202113333SA (pt) |
| WO (1) | WO2020249980A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023148680A1 (en) * | 2022-02-04 | 2023-08-10 | Advanced Accelerator Applications | Methods for large scale synthesis of radionuclide complexes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2284180B1 (en) | 2003-03-03 | 2015-09-09 | Dyax Corp. | Uses of peptides that specifically bind HGF receptor (cMET) |
| NO20034350D0 (no) | 2003-09-29 | 2003-09-29 | Amersham Health As | Optisk avbilding av kolorektal kreft |
| GB201013808D0 (en) | 2010-08-18 | 2010-09-29 | Ge Healthcare Ltd | Peptide radiotracer compositions |
| GB201103696D0 (en) * | 2011-03-04 | 2011-04-20 | Ge Healthcare Ltd | Technetium labelled peptides |
| US20130195756A1 (en) * | 2012-01-31 | 2013-08-01 | General Electric Company | 99mTc IMAGING AGENTS AND METHODS OF USE |
| GB201223029D0 (en) * | 2012-12-20 | 2013-02-06 | Ge Healthcare Ltd | Chelating agents |
| CN109824765B (zh) * | 2018-10-16 | 2020-11-17 | 哈尔滨医科大学 | 68Ga标记AEEA修饰c-Met分子成像探针及制备与应用 |
-
2020
- 2020-06-15 WO PCT/GB2020/051442 patent/WO2020249980A1/en unknown
- 2020-06-15 CA CA3142866A patent/CA3142866A1/en active Pending
- 2020-06-15 CN CN202080057163.7A patent/CN114222592A/zh active Pending
- 2020-06-15 KR KR1020227000907A patent/KR20220034777A/ko unknown
- 2020-06-15 BR BR112021025124A patent/BR112021025124A2/pt unknown
- 2020-06-15 JP JP2021574189A patent/JP2022537946A/ja active Pending
- 2020-06-15 EP EP20734286.6A patent/EP3983019A1/en active Pending
- 2020-06-15 US US17/618,850 patent/US20220273830A1/en active Pending
- 2020-06-15 SG SG11202113333SA patent/SG11202113333SA/en unknown
- 2020-06-15 GB GB2115731.8A patent/GB2598676A/en not_active Withdrawn
- 2020-06-15 MX MX2021015467A patent/MX2021015467A/es unknown
- 2020-06-15 GB GB2009064.3A patent/GB2589398B/en active Active
- 2020-06-15 AU AU2020291197A patent/AU2020291197A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021015467A (es) | 2022-01-24 |
| AU2020291197A1 (en) | 2022-01-27 |
| GB2589398B (en) | 2023-02-15 |
| CN114222592A (zh) | 2022-03-22 |
| US20220273830A1 (en) | 2022-09-01 |
| CA3142866A1 (en) | 2020-12-17 |
| EP3983019A1 (en) | 2022-04-20 |
| GB2598676A (en) | 2022-03-09 |
| SG11202113333SA (en) | 2021-12-30 |
| GB202009064D0 (en) | 2020-07-29 |
| GB202115731D0 (en) | 2021-12-15 |
| JP2022537946A (ja) | 2022-08-31 |
| KR20220034777A (ko) | 2022-03-18 |
| GB2589398A (en) | 2021-06-02 |
| WO2020249980A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
| Castaldi et al. | Can “early” and “late” 18F-FDG PET–CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? | |
| Fleckenstein et al. | F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial | |
| BR0210886A (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal | |
| Rodriguez-Ruiz et al. | Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies | |
| Qu et al. | Advances and challenges in intensity-modulated radiotherapy for nasopharyngeal carcinoma | |
| Pinkawa et al. | Application of a hydrogel spacer for postoperative salvage radiotherapy of prostate cancer | |
| MX2023010328A (es) | Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso. | |
| Hasan et al. | Comparison of planned versus actual dose delivered for external beam accelerated partial breast irradiation using cone-beam CT and deformable registration | |
| Jouglar et al. | Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial | |
| Correa et al. | Radiotherapy in soft-tissue sarcoma of the extremities | |
| BR112021025124A2 (pt) | Composto, composição farmacêutica, kit para a preparação da composição farmacêutica, métodos de imagiologia e radioterapia do corpo de mamífero, de detecção, diagnóstico, prognóstico, previsão do resultado, cirurgia, estadiamento, tratamento, terapia, radioterapia, monitoramento do tratamento, monitoramento da progressão da doença e/ou monitoramento da terapia e de obtenção de uma imagiologia de locais e/ou tratamento de condições associadas à superexpressão ou localização de cmet in vivo, e, uso | |
| Barry et al. | The impact of active breathing control on internal mammary lymph node coverage and normal tissue exposure in breast cancer patients planned for left-sided postmastectomy radiation therapy | |
| del Valle Aguilera et al. | Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction (α/β= 3Gy) at 2 cm 3 of vagina | |
| Varoquaux et al. | Endocrine tumors associated with the vagus nerve | |
| WO2019055776A3 (en) | Compositions and methods for treatment of diseases involving cxcl1 function | |
| Girelli et al. | Image-guided intensity-modulated radiotherapy for prostate cancer employing hypofractionation and simultaneous integrated boost: Results of a consecutive case series with focus on erectile function | |
| Kim et al. | Combined interstitial and surface high-dose-rate brachytherapy treatment of squamous cell carcinoma of the hand | |
| Vorobyov et al. | Ultrahypofractionated Adjuvant Proton Therapy for Localized Stage Breast Cancer: Early Toxicity Report | |
| Lee et al. | CTNI-26. SURGICAL WINDOW OF OPPORTUNITY TRIAL OF NAVTEMADLIN (KRT 232; AMG232) IN PATIENTS WITH RECURRENT GLIOBLASTOMA | |
| Savelli et al. | Somatostatin receptors in an anaplastic oligodendroglioma relapse evidenced by 68ga dotanoc Pet/Ct | |
| Hirokawa et al. | Investigation of the Optimum S-1 Dosing Schedule of Concurrent Chemoradiotherapy for T2N0 Glottic Cancer: A Comparison of Alternate-Day Administration Versus Daily Administration | |
| Tsoli et al. | DIPG-05. COMBINATION OF SYNTHETIC RETINOID FENRETINIDE WITH RECEPTOR TYROSINE KINASE INHIBITOR PONATINIB AS A POTENTIAL NEW APPROACH AGAINST DIFFUSE INTRINSIC PONTINE GLIOMA | |
| RU2586042C1 (ru) | Способ лечения рака прямой кишки | |
| Vanneste et al. | Means for Target Volume Delineation and Stabilisation: Fiducial Markers, Balloons and Others |